Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients
- First Posted Date
- 2011-12-05
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 48
- Registration Number
- NCT01485302
- Locations
- 🇫🇷
Investigational Site Number 250001, Pierre Bénite, France
🇳🇱Investigational Site Number 528001, Leiden, Netherlands
🇧🇬Investigational Site Number 100001, Sofia, Bulgaria
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Insulin glargine /lixisenatide Fixed Ratio Combination
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 323
- Registration Number
- NCT01476475
- Locations
- 🇨🇱
Investigational Site Number 152403, Santiago, Chile
🇨🇿Investigational Site Number 203401, Plzen, Czech Republic
🇨🇿Investigational Site Number 203405, Praha 8, Czech Republic
SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients
- First Posted Date
- 2011-11-17
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 61
- Registration Number
- NCT01472887
- Locations
- 🇺🇸
Investigational Site Number 840003, Augusta, Georgia, United States
🇧🇪Investigational Site Number 056002, Gent, Belgium
🇨🇿Investigational Site Number 203002, Brno, Czechia
Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2014-11-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 50
- Registration Number
- NCT01470456
- Locations
- 🇫🇷
Investigational Site Number 250006, Lille Cedex, France
🇦🇹Investigational Site Number 040002, Graz, Austria
🇫🇷Investigational Site Number 250004, Creteil Cedex, France
Safety of Single Doses of SAR113945 and Efficacy and Safety of a New Formulation Given Into the Knee in Osteoarthritis Patients / Part I
- First Posted Date
- 2011-11-02
- Last Posted Date
- 2012-08-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 24
- Registration Number
- NCT01463488
- Locations
- 🇩🇪
Investigational Site Number 276001, Berlin, Germany
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
- First Posted Date
- 2011-11-01
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 191
- Registration Number
- NCT01463397
- Locations
- 🇵🇱
Investigational Site Number 616001, Bydgoszcz, Poland
🇺🇸Investigational Site Number 840014, Tucson, Arizona, United States
🇺🇸Investigational Site Number 840038, Santa Ana, California, United States
Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: INSULIN GLARGINE HOE 901
- First Posted Date
- 2011-10-28
- Last Posted Date
- 2013-01-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 89
- Registration Number
- NCT01461577
- Locations
- 🇯🇵
Administrative office, Tokyo, Japan
Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients
- First Posted Date
- 2011-10-26
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 538
- Registration Number
- NCT01459809
- Locations
- 🇹🇷
Investigational Site Number 792-002, Kutahya, Turkey
🇦🇪Investigational Site Number 784-001, Dubai, United Arab Emirates
🇪🇬Investigational Site Number 81802, Cairo, Egypt
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 244
- Registration Number
- NCT01457911
- Locations
- 🇨🇳
Investigational Site Number 156023, Jinan, China
🇨🇳Investigational Site Number 156021, Shenyang, China
🇨🇳Investigational Site Number 156024, Tianjin, China
A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
- Conditions
- Neoplasm Malignant
- Interventions
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2014-10-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 59
- Registration Number
- NCT01455532
- Locations
- 🇺🇸
Investigational Site Number 840004, Los Angeles, California, United States
🇺🇸Investigational Site Number 840010, Augusta, Georgia, United States
🇺🇸Investigational Site Number 840007, St Louis, Missouri, United States